Benzinga · Sep 11, 2026
Barclays Maintains Overweight on Omada Health, Raises Price Target to $27
Barclays analyst Saket Kalia maintains Omada Health (NASDAQ:OMDA) with a Overweight and raises the price target from $25 to $27.
OM
NASDAQ · OMDA
Omada Health
Healthcare · Medical - Healthcare Information Services
$19.67
Up+$0.09 (+0.46%)
Updated Sep 17, 2026, 1:30 AM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 891.49M
- P/E ratio
- -37.65
- Dividend yield
- 0.00%
- 52-week range
- $10.28 – $26.92
- Volume
- 1.66M
- Avg. volume
- 693.59K
Price performance
OMDA price history
1M range · 0 trading sessions · Daily adjusted prices
OMDA does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest OMDA news
The latest Smart Investors Daily articles mentioning OMDA.
Stock researchCompany · Overview
OMDA research
Overview
Company profile and research snapshot.
Company profile
Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The Company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $24.67
- Implied upside
- —
- Analysts
- 16
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 14, 2026 | Freedom Capital Markets | Buy | — |
| Sep 11, 2026 | Barclays | Overweight | — |
| Sep 11, 2026 | Needham | Buy | — |
| Sep 11, 2026 | BTIG | Buy | — |
| Aug 14, 2026 | JP Morgan | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 11, 2026
Needham Reiterates Buy on Omada Health, Maintains $28 Price Target
Needham analyst Ryan MacDonald reiterates Omada Health (NASDAQ:OMDA) with a Buy and maintains $28 price target.
Benzinga · Sep 11, 2026
BTIG Reiterates Buy on Omada Health, Maintains $35 Price Target
BTIG analyst David Larsen reiterates Omada Health (NASDAQ:OMDA) with a Buy and maintains $35 price target.
SeekingAlpha · Sep 11, 2026
Omada Health, Inc. (OMDA) Analyst/Investor Day Transcript
Omada Health, Inc. (OMDA) Analyst/Investor Day September 10, 2026 1:00 PM EDTCompany ParticipantsSteven Cook - Chief Financial OfficerSean Duffy -...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
